| [1] |
王卫东，倪嘉延，许林锋.对比微球与传统碘油栓塞治疗原发性肝癌疗效[J].中华介入放射学电子杂志，2014，2(3):56-60.
|
| [2] |
Kerr DJ. Microparticulate drug delivery systems as an adjunct to cancer treatment[J]. Cancer Drug Delivery，2009，4(1):55.
|
| [3] |
张浩.肝癌肝动脉栓塞用载药微球的研究现状及进展[J].医学临床研究，2017，34(2):341-344.
|
| [4] |
Savic LJ, Chapiro J, Geschwind JH. Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma：update and future prospects[J]. Hepatobiliary Surg Nutr，2017，6(1):7-21.
|
| [5] |
Ni JY, Sun HL, Chen YT，et al. Drug-eluting bead transarterial chemoembolization in the treatment for unresectable soft tissue sarcoma refractory to systemic chemotherapy：a preliminary evaluation of efficacy and safety[J]. J Cancer Res Clin Oncol，2018，144(1):157-163.
|
| [6] |
Han S, Zhang X, Zou L，et al. Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis[J]. PloS One，2014，9(8):e102686.
|
| [7] |
Vasnani R, Ginsburg M, Ahmed O，et al. Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplantation[J]. Hepatobiliary Surg Nutr，2016，5(3):225-233.
|
| [8] |
Kodama Y, Matsui T, Tsuji K，et al. Is drug-eluting bead transcatheter arterial chemoembolization（TACE）associated with better tumor response than conventional TACE in meta-analysis? [J]. Hepatol Res，2016，45(12):1258-1259.
|
| [9] |
Scartozzi M, Baroni GS, Faloppi L，et al. Trans-arterial chemo embolization（TACE），with either lipiodol（traditional TACE）or drug-eluting microspheres（precision TACE，pTACE）in the treatment of hepatocellular carcinoma：efficacy and safety results from a large mono-institutional analysis[J]. J Exp Clin Cancer Res，2010，29:164.
|
| [10] |
Gaba RC, Emmadi R, Parvinian A，et al. Correlation of doxorubicin delivery and tumor necrosis after drug-eluting bead transarterial chemoembolization of rabbit VX2 liver tumors[J]. Radiology，2016，280(3):752-761.
|
| [11] |
Liu YS, Lin CY, Chuang MT，et al. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. BMC Gastroenterol，2018，18(1):124.
|
| [12] |
Sun J, Zhou G, Zhang Y，et al. Comprehensive analysis of common safety profiles and their predictive factors in 520 records of liver cancer patients treated by drug-eluting beads transarterial chemo-embolization[J]. Medicine（Baltimore），2018，97(26):e11131.
|
| [13] |
Heaysman CL, Philips GJ, Lloyd AW，et al. Unusual behaviour induced by phase separation in hydrogel microspheres[J]. Acta Biomater，2017，53:190-198.
|
| [14] |
Fohlen A, Tasu JP, Kobeiter H，et al. Transarterial chemoembolization（TACE）in the management of hepatocellular carcinoma：Results of a French national survey on current practices[J]. Diagn Interv Imaging，2018，99(9):527-535.
|
| [15] |
Lammer J, Malagari K, Vogl T，et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma：results of the PRECISION V study[J]. Cardiovasc Intervent Radiol，2010，33(1):41-52.
|
| [16] |
Fuchs K, Bize PE, Dormond O，et al. Drug-eluting beads loaded with antiangiogenic agents for chemoembolization：in vitro sunitinib loading and release and in vivo pharmacokinetics in an animal model[J]. J Vasc Interv Radiol，2014，25(3):379-387.
|
| [17] |
Pawlik TM, Reyes DK, Cosgrove D，et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma[J]. J Clin Oncol，2011，29(30):3960-3967.
|
| [18] |
赵倩，颜志平.载药微球经导管动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志，2017，26(11):1052-1056.
|
| [19] |
Liu Y, Huang W, He M，et al. Efficacy and safety of CalliSpheres? drug-eluting beads transarterial chemoembolization in barcelona clinic liver cancer stage C patients[J]. Oncol Res，2018. [Epub ahead of print]
|
| [20] |
Sánchez-Delgado J, Vergara M, Machlab S，et al. Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization[J]. Eur J Gastroenterol Hepatol，2018，30(12):1453-1460.
|
| [21] |
Zhou GH, Han J, Sun JH，et al. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres? beads in Chinese hepatocellular carcinoma patients[J]. BMC cancer，2018，18(1):644.
|
| [22] |
Ludwig JM, Zhang D, Xing M，et al. Meta-analysis：adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma[J]. Eur Radiol，2017，27(5):2031-2041.
|
| [23] |
Levy J, Zuckerman J, Garfinkle R，et al. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases：a systematic review and meta-analysis[J]. HPB （Oxford），2018，20(10):905-915.
|
| [24] |
Akinwande O, Philips P, Scoggins C，et al. Radioembolization versus chemoembolization（DEBDOX）for the treatment of unresectable hepatocellular carcinoma：a propensity matched study[J]. Anticancer Res，2016，36(1):239-246.
|
| [25] |
Melchiorre F, Patella F, Pescatori L，et al. DEB-TACE：a standard review[J]. Future Oncol，2018. doi： 10.2217/fon-2018-0136. [Epub ahead of print] |
| [26] |
Yang Q, Jin X, Ye F，et al. Safety and efficacy analysis of DEB-TACE treatment in elderly patients with hepatocellular carcinoma：a comparative cohort study[J]. Oncol Res，2018. doi： 10.3727/096504018X15223171140640. [Epub ahead of print] |
| [27] |
Akinwande O, Kim D, Edwards J，et al. Is radioembolization （（90）Y）better than doxorubicin drug eluting beads（DEBDOX）for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis[J]. Surg Oncol，2015，24(3):270-275.
|
| [28] |
Cucchetti A, Trevisani F, Cappelli A，et al. Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma[J]. Dig Liver Dis，2016，48(7):798-805.
|
| [29] |
Malagari K, Iezzi R, Goldberg SN，et al. The ten commandments of chemoembolization：expert discussion and report from Mediterranean Interventional Oncology（MIOLive）congress 2017[J]. Eur Rev Med Pharmacol Sci，2018，22(2):372-381.
|
| [30] |
田建明，王飞，叶华，等.肝癌的规则性、变异性供血及其临床意义[J].中华放射学杂志，1994，2:93-96.
|
| [31] |
Lee KH, Liapi E, Vossen JA，et al. Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer：evaluation with MR imaging and implication for therapy[J]. J Vasc Interv Radiol，2008，19(10):1490-1496.
|
| [32] |
Lencioni R, de Baere T, Burrel M，et al. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC bead （DEBDOX）：technical recommendations[J]. Cardiovasc Intervent Radiol，2012，35(5):980-985.
|
| [33] |
Lencioni R, Aliberti C, Baere TD，et al. Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads：technical recommendations[J]. J Vasc Interv Radiol，2014，25(3):365-369.
|
| [34] |
Chang PY, Huang CC, Hung CH，et al. Multidisciplinary taiwan consensus recommendations for the use of DEBDOX-TACE in hepatocellular carcinoma treatment[J]. Liver cancer，2018，7(4):312-322.
|
| [35] |
Luz JH, Luz PM, Martin HS，et al. DEB TACE for intermediate and advanced HCC-initial experience in a brazilian cancer center[J]. Cancer Imaging，2017，17(1):5.
|
| [36] |
陈刚，张鼎，应亚草，等.国产载药微球经动脉化疗栓塞治疗不可切除原发性肝癌的临床研究[J].浙江大学学报（医学版），2017，46(1):44-51.
|
| [37] |
Nishi M, Saeki I, Yamasaki T，et al. Hemobilia immediately after transcatheter arterial chemoembolization using drug-eluting beads for hepatocellular carcinoma with intrahepatic bile duct invasion[J]. Hepatol Res，2018，48(4):329-332.
|
| [38] |
Lee S, Kim KM, Lee SJ，et al. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma：comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study[J]. Acta Radiol，2017，58(2):131-139.
|
| [39] |
Cavalcante RN, Nasser F, Motta-Leal-Filho JM，et al. Occurrence of vascular lake phenomenon as a predictor of improved tumor response in HCC patients that underwent DEB-TACE[J]. Cardiovasc Intervent Radiol，2017，40(7):1044-1051.
|
| [40] |
Kloth C, Thaiss WM, K?rgel R，et al. Evaluation of texture analysis parameter for response prediction in patients with hepatocellular carcinoma undergoing drug-eluting bead transarterial chemoembolization（DEB-TACE）using biphasic contrast-enhanced CT image data：correlation with liver perfusion CT[J]. Acad Radiol，2017，24(11):1352-1363.
|